Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18-49 Years of Age Enrolled at Center for Indigenous Health Sites. - Hammitt LL; Buchwald UK; McCauley J; Shekar T; Fu W; Cheon K; Sterling T; Tamms G; Banniettis N; Musey L; LeBlanc JJ; Weatherholtz R; et al. (Vaccines, 2025)